Web Research

Web Research — what the public record adds to the filing thesis

The bottom line. The web mostly confirms what the FY2025 20-F and the most recent quarterlies disclose — Yatsen's skincare-led turnaround is real (FY25 +26.7% revenue, Skincare 53% of mix and +63.5% YoY, first non-GAAP profit year since the IPO bust) — but it adds three thesis-relevant updates that are NOT in the annual report. First, the US$120M founder/Trustar convertible self-deal was rescued from its shareholder objection by Hillhouse — already a 13.8% holder of Class A shares — joining as a co-investor when the first tranche finally closed on May 21, 2026 [1], which both validates and dilutes the "controlled-company self-deal" narrative carried by the People and Forensics tabs. Second, Q1 FY2026 is the first quarter in roughly a year where the turnaround stalled at the margin line — revenue growth decelerated to +22.5%, but operating expenses jumped +32.5%, swinging the company back to a non-GAAP loss (RMB57M vs RMB7M profit a year earlier) [2]. Third, the Maeshiro IPO securities class action (filed Oct 2022) was dismissed with prejudice in July 2025 with no appeal [3] — a cleared overhang that the filings disclose but the market chatter still treats as live. The public-domain news flow contains no other thesis-changing event: no SEC investigation, no auditor change, no short-seller campaign, no insider-selling scandal (the March 2026 "sales" widely reported on aggregator sites are Form 3 initial-ownership filings, not transactions — flagged below). Sell-side coverage is essentially absent; independent analyst sentiment has rotated from "early turnaround" Buys (2023-24) into "fairly valued / convoluted" Holds (2025-26) as the easy doubling already happened.

1 — Hillhouse rescues the convertible (May 21, 2026)

The FY2025 20-F filed April 29, 2026 disclosed that the first tranche of the March 11, 2026 US$120M Note Purchase Agreement with Trustar Capital and CEO Jinfeng Huang had not yet closed, because "a significant shareholder of ours raised objections" and was negotiating to participate [4]. Twenty-two days later, the company announced the first tranche had closed — and identified the objecting shareholder as Hillhouse, which joined Trustar and Huang as a co-investor in the Polaris Veritas vehicle on May 21, 2026 (PR Newswire / Stock Titan 6-K, 2026-05-21). The CEO then framed the closing on the Q1 FY2026 earnings call as "a powerful testament to our shareholders' long-term confidence in Yatsen's strategic direction and future value" [1].

Why this matters more than the filing alone shows. Hillhouse is not a new entrant — it already held 258,521,262 Class A shares (13.8% of issued shares, 1.9% of voting power) as of February 28, 2026 per the FY2025 20-F principal-shareholders table [5]. Doubling down at a US$4.63 conversion price (a 20% premium to the recent VWAP and a ~45% premium to the current US$3.17 ADS) at 1.5% coupon (Stock Titan note-terms summary) is an unusual move for an existing long-only China-strategy holder if the company were viewed as terminal-value-impaired. The Forensics tab flagged the original deal as a "self-deal" governance risk; the web settles the open question the 20-F left hanging — the objection was resolved by inclusion, not by walk-away, and the structure now has a third-party validator on the same terms as the insider.

So-what for the stock. Removes one near-term overhang (deal failure risk) and partially answers the controlled-company critique (an outside institution co-validated the terms). Does not remove the underlying dilution math — if both tranches convert, Polaris Veritas takes roughly US$120M/$4.63 ≈ 26M ADSs plus 10% warrants on top, ~3M+ ADSs net new on a ~95M-ADS float. The CEO's vehicle still gets a 4% IRR floor that outside Class A holders do not.

Priced in? Hillhouse participation was announced May 21, 2026; the stock was ~$3.50 the day before and trades at $3.17 today. The market reaction was negative, suggesting investors read the closing more as "founder needs the money to land" than as "Hillhouse blessing." The validation signal is, on the evidence, not yet priced in.

2 — Q1 FY2026 — the turnaround is intact at the top line, gone at the margin line

The Q1 FY2026 release confirms the headline narrative — +22.5% revenue, +58.5% skincare, record 80.2% gross margin [6] — but the operating leverage went the wrong way. Operating expenses jumped 32.5% YoY, taking the opex ratio from 83.2% to 89.9%, and the company swung from a small non-GAAP profit (RMB7.1M, +0.9% margin) a year earlier to a non-GAAP loss of RMB57.3M (-5.6% margin) [2]. GAAP net loss widened to RMB61.9M from RMB5.6M. The CFO framed this as "we selectively deployed resources to scale and strengthen our core brands" — i.e. marketing reinvestment for skincare — but the Q2 FY2026 guidance of RMB1.20-1.30B (+10-20%) [7] implies further deceleration from Q1's 22.5%, well below the +47.5% pace of Q3 FY2025.

This is the gap the Bamboo Works May 2025 piece flagged when the CEO "declared turnaround" on Q1 FY2025's RMB7M non-GAAP profit (Bamboo Works, 2025-05-19) — the company's non-GAAP "turnaround" runs through marketing intensity, and the first quarter where that lever was pulled hard again has unwound it.

So-what for the stock. Resets the inevitable bull-case anchor — the FY2025 non-GAAP positive year that the CFO Yang called "a pivotal milestone" [8]. Reinforces the structural critique that Yatsen's gross-margin uplift is mortgaged to a high and inelastic selling-and-marketing line. The next two quarters are the test of whether the FY2025 profit was a budget-cycle phenomenon or a structural rebase.

Priced in? The stock fell from ~$5.85 at end-March 2026 to $3.17 today — a -46% drawdown over the period covering the Q4 FY2025 print, the FY2025 20-F filing, the Q1 FY2026 print, and the convertible closing. Some of the margin disappointment is in the price; the Q2 guide deceleration came at the print itself. Consensus models for FY2026 are not visible (no sell-side coverage on Yahoo / SeekingAlpha shows analyst targets — investingpro lists "fair value undervalued" but no published consensus).

3 — The March 2026 "insider sale" headlines are Form 3 filings, not transactions — caveat

Several stock-aggregator sites (Stockcircle.com, parts of the SimplyWall.St/Yahoo Finance feed) report what looks like a wave of massive insider sales between March 16-18, 2026:

This is data exhaust, not a wave of insider selling. The matching SEC filings on the YSG docket are Form 3 — Initial Statement of Beneficial Ownership (Stock Titan SEC filings list). A Form 3 is the first filing made when someone becomes a Section 16 reporting person (officer, director, or 10% holder) and merely discloses their existing holdings as of that date — it is not a transaction. Stockcircle's "Sale" categorization is an aggregator artifact, not a fact about insider behavior. The give-away in the data is that founder Huang's reported "sale" of ~294M shares (~US$1.16B) is precisely consistent with the FY2025 20-F's principal-shareholder table disclosing him as holding 643,671,174 shares with 90.7% voting power (Class A + Class B 600.6M) [5] — he did not liquidate a third of his stake in a single day; the Form 3 disclosed a portion of his existing holdings under a new reporting alignment.

So-what for the stock. None — but if a PM sees the Stockcircle screenshot and reads it as a $1.2B founder dump, that is a false red flag that has spread on aggregator sites without correction. Flag and move on. Priced in? Irrelevant — there is no underlying transaction to price.

4 — Maeshiro v. Yatsen — dismissed with prejudice, July 2025, no appeal

The most prominent live overhang on Yatsen in 2022-2024 was the Maeshiro v. Yatsen Holding Limited securities class action (S.D.N.Y., No. 1:22-cv-08165), which alleged the November 2020 IPO offering documents and subsequent disclosures concealed that Perfect Diary and Little Ondine cosmetic sales were materially declining at the time of the IPO and through 2021. Multiple investor-firm press releases (Howard G. Smith, Robbins Geller, Levi & Korsinsky) circulated through late 2022.

The FY2025 20-F confirms the matter is closed: defendants' motion to dismiss the amended complaint was granted on July 22, 2024; in July 2025 the court denied leave to amend further and dismissed with prejudice; plaintiffs did not appeal [3]. External web coverage of the resolution is sparse — investor-alert legal sites continue to surface the older 2022 filing notices in search results, which a PM scanning headlines could misread as a live action.

So-what for the stock. A real, fully-resolved litigation overhang. Removes a small probability tail of a damages payout and the management distraction the 20-F itself flags. Should incrementally lift the multiple the market is willing to assign to a foreign private issuer with a China-VIE structure — but only marginally, because the underlying risk factors (HFCAA, VIE, dual-class control) remain. Priced in? Almost certainly — the dismissal was in the public record for ~11 months before today and the stock has moved on multiple other drivers since. Mention as resolved status, not as a thesis driver.

5 — Independent analyst sentiment has rotated to "fairly valued / convoluted"

No major-sell-side broker publishes a covered price target visible on the standard aggregators (Yahoo, SeekingAlpha "Wall Street Ratings", Investing.com). The only published independent-analyst track on Yatsen runs through the SeekingAlpha contributor stream — useful as a sentiment thermometer, not as consensus.

The arc maps cleanly onto the stock — Buys initiated when the ADS traded around the underlying net cash (mid-2023 through mid-2024), downgraded to Hold once the ADS doubled past $5 (March 2025), and a sustained skeptical voice through the entire 2025 run-up to the high-$8 print and the subsequent collapse. The current $3.17 print sits below the 2023-24 Buy levels on aggregator data, but no analyst has stepped back in to upgrade — silence is itself a signal. The relevant data point for the PM: (SeekingAlpha YSG analysis stream) — last bull thesis is more than two years old; last published view is "Convoluted".

So-what for the stock. Limited sell-side coverage means no visible "consensus" floor and no broker-distribution buying pressure on positive news. The independent sentiment skew is bearish-to-neutral. A non-trivial part of the recent drawdown is sentiment normalization rather than fundamentals. Priced in? Largely — the latest skeptical pieces from late 2025 preceded the FY2025 print upside. The bull case the price is not reflecting is the FY26 evidence of structural margin (vs. budget-cycle margin), which Q1 FY2026 just undermined.

6 — R and D claim — confirmed scale, but contextual: $100M cumulative is not a global-scale moat

The PR Newswire 2026-05-07 release (Yatsen research-and-development, 2026-05-07) cites "approximately US$100 million in research and development since 2020", three research centres (Shanghai, Toulouse, Guangzhou), and "240+ patents". The annual income-statement numbers corroborate this — RMB91.8M to 146.0M per year (US$13-21M) over FY2021-2025 sums to roughly US$80-90M, with FY2025's RMB146.0M the highest year. Research and development intensity has held a steady 3.3-3.9% of revenue, which is above most domestic Chinese masstige peers but well below global prestige operators (L'Oréal at roughly 3.4% of revenue but on a €40B-plus base; Estée Lauder several times this scale).

So-what for the stock. Validates the "science-led beauty" narrative the CEO and Chief Scientific Officer have been pushing in earnings calls — it is real spend, not a slogan. Does not, by itself, build a global moat against Estée Lauder or L'Oréal in China. The research-and-development thesis remains a premium-vs-domestic-peer differentiator, not a premium-vs-global-prestige differentiator. Priced in? Yes — this is the management narrative the bull case already runs through.

7 — Q2 FY2024 guidance cut — a reminder management will mark down when needed

On July 10, 2024 — six weeks before the Q2 FY2024 print — the company issued a rare mid-quarter pre-announcement, "Yatsen Prudently Adjusts Revenue Outlook for the Second Quarter of 2024" [9], citing subdued China beauty consumption. Q2 FY2024 ultimately came in at -7.5% YoY. This is the only voluntary mid-quarter guidance cut in the news ledger over the last three years. The Q2 FY2026 guide of +10-20% (vs. +22.5% just delivered) is not a cut in the same form, but it is a deceleration the market should track to see whether management defends or marks down again ahead of the August print.

So-what for the stock. Calibration data point — management has shown willingness to pre-announce a miss rather than surprise. That is positive for credibility but means the next mid-cycle pre-announcement, if one comes, should be taken at face value.

8 — MSCI ESG A rating retained (2024, two-year stretch)

The 2023 ESG report (published Sept 2024) noted Yatsen retained an MSCI ESG A rating, "the only Chinese beauty company at A for two years running" [10]. Modest positive, relevant only to ESG-mandated capital — and even there, the China-VIE / dual-class structure caps how much benefit flows. Not a thesis driver; mentioned for completeness.

Recent and still-live news — reference layer

The corpus news/ section indexes 31 items spanning 2023-2026; the table below carries every item from the corpus plus the May 21, 2026 Hillhouse-closing news that broke after the news file was compiled. Materiality is graded High where the item would move the thesis or the price, Medium where it adds incremental color, Low where it is calendar/announce-of-announce. Live-thesis items older than 3 months are retained when still relevant.

The cadence is striking. From the IPO-disclosure class action filing in late 2022 to the NYSE-listing crisis (cured by the March 2024 1-for-5 ADS ratio change), to the FY2023 revenue trough (-7.9%), to the Q2 FY2024 guidance cut, to the skincare-led re-acceleration that runs from Q1 FY2025 through Q3 FY2025 (Skincare YoY: +47.7%, +78.7%, +83.2%), and into the Q4 FY2025 non-GAAP profit print — the run from Q1 FY2025 to Q3 FY2025 is the inflection that the late-2025 stock rally to ~$11 priced. The Q1 FY2026 stall plus the convertible saga are what the price has been giving back since.

Specialist-question coverage — what the web closed and what it left open

The Industry, Warren, Quant, Forensic, Sherlock, Historian, Moat, and Competition specialists collectively asked ~63 web-research questions. The answers that change the thesis are promoted above. The remainder live in the reference grid below — short answers with their best web source, the evidence weight, and what (if anything) remains genuinely unresolved.

Governance and people signals (web side)

• Founder Jinfeng Huang (b. 1984) — Founder, Chairman, CEO, holds 32.0% of issued shares and 90.4% of voting power as of February 28, 2026 per 20-F [11] (filing-side anchor for the controlled-company structure). No web-side governance controversy, regulatory action, or insider-sale event surfaced in the period. He is the CO-INVESTOR on the convertible notes, not the principal — a self-deal structure that the Forensics tab properly flagged and that Hillhouse now partly neutralizes.
• CFO Donghao Yang (b. 1972) — Director and CFO. Frames financial commentary on every release. Q1 FY2026 commentary used "selectively deployed resources" to explain opex growth — a phrasing the PM should track for repetition next quarter.
• CSO Jing Cheng (b. 1972) — Chief Scientific Officer; the visible voice on the research-and-development narrative the company is pushing.
• External institutional anchors — Hillhouse Entities 13.8% (now plus convertible-deal exposure); ZhenFund Entities 11.9%; HHLR + Hillhouse Investment Management as the operating units [5].
• Insider activity (genuine) — the only meaningful web-visible activity in the period is the March 2026 Form 3 filings (aggregator-mislabelled, see Finding 3) and the May 26, 2026 6-K disclosing the convertible-tranche closing. Neither is an open-market sale or buy.
• Glassdoor signal (low n) — Singapore office Glassdoor page returns minimal data with one current employee scoring 1.0 across all categories. Sample size too small to be a signal — flagging it only because the dossier surfaced it.

What new external industry evidence the web adds beyond the Industry tab

• Tmall + JD + Douyin combined online beauty growth recorded single-digit YoY in Q3 2025 per the CEO citing National Bureau of Statistics in the Q1 FY2026 call. Confirms the structural deceleration in the once-explosive online-beauty channel.
• Greater-China weakness reported by Estée Lauder, L'Oréal, Shiseido through 2024-25 is the structural tailwind on which Yatsen's skincare push is gaining share — a confirmation of the Industry tab's read.
• Maogeping (HK 1408) IPO'd late 2024 as a directly comparable domestic prestige listed peer. The HK market has, for now, valued Maogeping at a meaningful sales-multiple premium to Yatsen — relevant context if comparing valuations.
• NMPA efficacy-testing rules continue to mature but the web flow surfaced no enforcement event in the period that hits Yatsen specifically.

Research queries left open

Spelled out in the separate web-research-claude-queries.json. The two most important remaining unknowns the public record did not settle: (a) whether the Q1 FY2026 opex jump is structural reinvestment or a one-quarter timing item, which only the Q2 FY2026 print (August 2026) resolves; and (b) the timing and terms of the second tranche of the convertible — the press release said "later this year, subject to customary closing conditions". The first answers the margin-quality question; the second answers the residual dilution overhang.

References

1. Yatsen Holding Limited — Q1 FY2026 Earnings Release, CEO commentary on convertible closing with Hillhouse — p.1
2. Yatsen Holding Limited — Q1 FY2026 Earnings Release, Net loss / non-GAAP loss detail — p.3
3. Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 8 Financial Information — Maeshiro v. Yatsen disclosure — p.149
4. Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 3.D Risk Factors — Trustar / convertible note subsequent event — p.40
5. Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 6.E Major Shareholders table — p.144
6. Yatsen Holding Limited — Q1 FY2026 Earnings Release, Net Revenues / Operating Expenses — p.2
7. Yatsen Holding Limited — Q1 FY2026 Earnings Release, Q2 FY2026 Outlook — p.4
8. Yatsen Holding Limited — Q4 / Full Year FY2025 Earnings Release, CFO turnaround commentary — p.2
9. Yatsen Holding Limited — Indexed news corpus, July 10, 2024 mid-quarter guidance cut entry — p.1
10. Yatsen Holding Limited — Indexed news corpus, September 6, 2024 MSCI ESG A rating retention entry — p.1
11. Yatsen Holding Limited — FY2025 Annual Report (Form 20-F), Item 3.D Risk Factors — dual-class voting power — p.69